Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome. JOC. 2025;24(3s):441-448. doi:10.64149/J.Carcinog.24.3s.441-448